RNS Number: 6808 C AorTech International PLC 19 June 2019 19 June 2019. AorTech announces the appointment of Shore Capital and Corporate Limited as its Nominated Adviser and Shore Capital Stockbrokers Limited as Broker, with immediate effect. This follows the acquisition of Stockdale Securities Limited by Shore Capital Markets Limited..
RNS Number: 6780 C AorTech International PLC 19 June 2019. AorTech International plc, the licensor of the world's leading long-term implantable biostable polymer and developer of medical devices utilising the key properties of Elast-Eon TM, makes the following disclosures pursuant to Rule 17 and Schedule Two paragraph of the AIM Rules for Companies in...
RNS Number: 4731 C AorTech International PLC 17 June 2019. Gordon Wright, Non-Executive Director of AorTech, was a director of Calmed UK Limited, which entered administration on 3 March 2009 and was dissolved on 9 December 2010. The Joint Administrators' Final Progress Report for the period 3 June 2011 to 23 November 2011 indicated that there was a shortfall to the...
RNS Number: 8724 Y AorTech International PLC 14 May 2019. ·Growth in polymer licensing revenue from £404 k to over £460 k. ·Strong cash position of £2.4 million as at 31 March 2019.
RNS Number: 0375 O AorTech International PLC 24 January 2019 24 January 2019. AorTech is pleased to provide an update on recent developments, an addition to its patent portfolio, the appointment of a new Company Secretary and the move of the Company's administration office.. AorTech's novel "Leaflet Builder" software utilising Computational Fluid Dynamics has...
While revenues from licensing our polymer technology continues to be earned in US$, with the new product development work all being undertaken in the UK, the switch to reporting in Sterling better reflects the currency of the primary economic environment in which the Company operates. In the six months ended 30 September 2018, revenues increased by 13 per cent...
RNS Number: 1101 E AorTech International PLC 15 October 2018 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 7699 Z AorTech International PLC 05 September 2018 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 2868 Z AorTech International PLC 30 August 2018 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 7264 Y AorTech International PLC 23 August 2018 AorTech International plc. AorTech International plc, the medical device development company and licensor of the world class bio-stable polymer, Elast-Eon TM, announces that all resolutions put to shareholders at its Annual General Meeting held earlier today, were duly passed..
AorTech (AOR.L) 63.5p �9.3m AGM Statement from the medical device development company and licensor of the world class bio-stable polymer, Elast-EonTM . "Having recently completed a very successful fundraising, which was oversubscribed, AorTech is in the process of transitioning from a company which was focused on licensing its world class polymer technology to a medical device development business building upon the unique properties of the Elast-EonTM material. Since completing the fundraising in June 2018, AorTech has engaged with a number of partners to accelerate the commercialisation of its device portfolio. Each of the partners has made good progress in their respective areas. On the heart valve project, technology transfer has been completed with Vascular Flow Technologies Limited which is now actively engaged with John Ely, who joined the Company as a non-executive Director on 11 June 2018, on design optimisation
AorTech International Plc (AOR.L) Announced that its Annual General Meeting to be held later today where Bill Brown, Chairman of the company will make the statements regarding the completion of a very successful fundraising. Further the company informed that the polymer licensing business is performing to plan and continues to meet the Board's expectations.
RNS Number: 6117 Y AorTech International PLC 23 August 2018 AorTech International Plc. At its Annual General Meeting to be held later today, Bill Brown, Chairman of AorTech International Plc, the medical device development company and licensor of the world class bio-stable polymer, Elast-Eon TM, will make the following statement:-. "Having recently completed a...
RNS Number: 9248 V AorTech International PLC 26 July 2018 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 7797 V AorTech International PLC 25 July 2018. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 7783 V AorTech International PLC 25 July 2018. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
�Satisfactory settlement of litigation proceedings: resulting in net receipts of $339 k after costs.. �Loss for the year down 81%: loss from continuing operations reduced to $44 k.. �Year end cash balance: increased significantly to $591 k..
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    14.69M

Income Statement

Sales/Revenue
Gross Income
Operating Income
Net Interest Income
Pre-Tax Income
Consolidated Net Income
Non-Interest Income
Interest Income after Loan Loss Provision
Non-Operating Income
Operating Income (EBIT)
Net Income
Non-Interest Expense
Operating Expenses
Total Expense
Operating profit per share
EPS (Basic)
EPS (Diluted - Before Unusual Expense)
EPS (Fully Diluted)

Balance Sheet - Assets

Net Property, Plant & Equipment
Intangible Assets
Cash & Short Term Investments
Investments
Other Financial Assets
Inventories
Total Short Term Accounts Receivable
Total Accounts Receivable
Total Cash & Due from Banks
Premium Balance Receivables
Total Current Assets
Tangible Other Assets
Other Intangible Assets
Other Assets
Other Funds
Total Assets

Balance Sheet - Liabilities

Liabilities & Stockholders' Equity
Other Current Liabilities
Total Current Liabilities
Provision for Risks & Charges
Losses, Claims & Reserves
Other Liabilities
Total Liabilities

Balance Sheet - Other

Dividends Per Share (Gross)
Dividends Per Share
Dividends Per Share (1-yr Annual Growth)
Dividend payout per share
Common Shares
Common Shares Outstanding
Common Shares (EPS Basic)
Common Shares (EPS Diluted)
Closely Held Shares
Total Shareholders' Equity
Non-Equity Reserves
Retained Earnings
Total Equity
Pre-Tax Margin
Net Interest Margin
Gross Profit Margin
Net Margin
Operating Margin
P/E Ratio
Debt / EBITDA
Total Debt / Assets
Assets Per Employee
Current Ratio
Common Stock Par / Carry Value
Enterprise Value
Market Value
Market Capitalisation
Dividend Yield
Dividend Yield - Security
Cash Dividend Coverage Ratio

Miscellaneous

Total Debt
Restricted Cash
Exchange Rate Effect
Incomes Taxes
Net Change in Cash
Income Tax Payable
Cash Only
Cash Dividends Paid
Convertible Debt
Long Term Debt
Short Term Debt
Asset Turnover
EBITDA
Operating Income After Interest Expense
Net Debt
Operating Income Before Interest Expense
Purchase / Sale of Investments
Other Appropriated Reserves
Creditors
Watchlist